The connections between the microbiome and human health are inspiring a new generation of therapeutics comprised of novel peptides, proteins, and cells.  Many of these agents face obstacles to commercialization that Symbiotic Health is uniquely poised to address.  We identify promising therapeutic candidates and advance them from laboratory proof-of-concept to clinic-ready product. 

We focus on the development of orally administered biologic therapeutics. Historically, biologics (therapeutics comprised of proteins and cells) have not been amenable to oral administration due to the limitations of existing drug delivery technologies.

Symbiotic Health has developed a proprietary oral enteric delivery platform for biologics and cells. Our process maintains the therapeutic agents in their solubilized or hydrated state, avoiding losses in functional activity through processing or gastrointestinal transit.